Conjugating antibodies to cytotoxic agents: getting the best of both worlds?

J Natl Cancer Inst. 2013 Dec 4;105(23):1765-6. doi: 10.1093/jnci/djt354. Epub 2013 Nov 16.
No abstract available

Publication types

  • News

MeSH terms

  • Ado-Trastuzumab Emtansine
  • Antibodies, Monoclonal, Humanized / pharmacology
  • Antineoplastic Agents / adverse effects*
  • Antineoplastic Agents / metabolism
  • Brentuximab Vedotin
  • Cytotoxins / adverse effects*
  • Cytotoxins / metabolism
  • Humans
  • Immunoconjugates / pharmacology
  • Immunotoxins / immunology
  • Immunotoxins / pharmacology*
  • Maytansine / analogs & derivatives
  • Maytansine / pharmacology
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Cytotoxins
  • Immunoconjugates
  • Immunotoxins
  • Maytansine
  • Brentuximab Vedotin
  • Trastuzumab
  • Ado-Trastuzumab Emtansine